Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives

18 Sept 2019

Abstract excerpt

The Kirsten rat sarcoma viral oncogene homolog (RAS)/v-raf-1 murine leukemia viral oncogene homolog 1 (RAF)/mitogen-activated protein kinase 1 (MAPK) signaling cascade is the most important oncogenic pathway in human cancers. Tumors leading mutations in the gene encoding for v-raf murine sarcoma viral oncogene homolog B (BRAF) serine-threonine kinase are reliant on the MAPK signaling pathway for their growth and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Melanoma and MAPK Pathways
Share to Thyroid Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31540406
DOI: 10.3390/cancers11091388

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesPMID 31540406Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

The role of BRAF in the pathogenesis of thyroid carcinoma.Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

[BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].Semantic proximity Read ↗

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

BRAF Inhibitor Therapy for Melanoma, Thyroid and Colorectal Cancers: Development of Resistance and Future ProspectsSemantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.Semantic proximity Read ↗

Genetic alterations in thyroid cancer mediating both resistance to BRAF inhibition and anaplastic transformation.Semantic proximity Read ↗

BRAF mutation and its inhibitors in sarcoma treatment.Semantic proximity Read ↗

Roles of RAS and BRAF mutations in thyroid carcinogenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.